Drawing for NAVASYS

USPTO serial 79167251

NAVASYS

Reviewed by CopyMark Law Group

Reg. 4920192Status 404
Filing date
Status date
Registration date
Mar 22, 2016
Examiner
VAGHANI, MAYUR C
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NAVASYS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Bacterial preparations other than for medical or veterinary use; biological preparations, other than for medical or veterinary purposes; chemical preparations for analyses in laboratories, namely, chemical preparations for scientific purposes, chemical preparations for use in industry other than for medical or veterinary purposes; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents for scientific purposes other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; chemical substances for analyses in laboratories, namely, chemical preparations for scientific purposes, chemical preparations for use in industry other than for medical or veterinary purposes; chemicals comprising glycolipid structure, namely, glycolipid for use in pharmaceutical preparations; cultures of microorganisms, other than for medical and veterinary use; industrial chemicals; lipopolysaccharide; preparations of microorganisms, namely, cultures of microorganisms, other than for medical and veterinary useSECTION 71 - CANCELLED—
005Adhesive bands for medical purposes; adhesive plasters for medical purposes; adhesive tapes for medical purposes; adjuvants for medical purposes; bacterial poisons; bacterial preparations for medical or veterinary use; bacteriological preparations for medical or veterinary use; biological preparations for medical purposes for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; biological preparations for veterinary purposes for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; capsules for medicines in the nature of capsules containing medicine for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; chemical preparations for medical purposes, namely, for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; chemical preparations for pharmaceutical purposes, namely, for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; chemical preparations for veterinary purposes, namely, for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; chemical reagents for medical or veterinary purposes; chemico-pharmaceutical preparations, namely, for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; chewing gum for medical purposes; collyrium; medicated compresses; cultures of microorganisms for medical and veterinary purposes; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drugs for medical purposes, namely, pharmaceutical preparations for the prevention of the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; Immunomodulators, namely, lipopolysaccharides, toll-like receptor (TLR) ligands, cyclic dinucleotide, bestatin in the nature of Ubenimex pidotimod as an immunostimulant, levamisole hydrochloride, cyclooxygenase inhibitor, prostaglandin receptor antagonist, prostaglandin receptor agonist, Thymic stromal lymphopoietin (TSLP) production inhibitor, adenylate cyclase inhibitor, omega-3 fatty acid, peroxisome proliferator-activated receptor (PPAR) agonist, dopamine receptor antagonist, dopamine receptor agonist, histamine receptor agonist, histamine receptor antagonist, serotonin receptor agonist, serotonin receptor antagonist, vasopressin receptor antagonist, vasopressin receptor agonist, muscarine receptor antagonist, muscarine receptor agonist, adrenergic receptor antagonist, adrenergic receptor agonist, angiotensin receptor agonist, GABA receptor agonist, thrombin receptor antagonist, thrombin receptor agonist, opioid receptor agonist, Adenosine diphosphate (ADP) receptor agonist, leukotriene receptor antagonist, leukotriene receptor agonist, melatonin receptor agonist, somatostatin receptor agonist, cannabinoid receptor agonist, sphingosine-1 phosphate receptor agonist, metabotropic glutamate receptor agonist, phospholipase A2 inhibitor, TGF-ß production inhibitor, and Th2 cytokine inhibitor all for the treatment and prevention of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; immunosuppressive agent, namely, pharmaceutical preparations in the nature of lipopolysaccharide, toll-like receptor (TLR) ligands, cyclic dinucleotide, bestatin in the nature of Ubenimex pidotimod as an immunostimulant, levamisole hydrochloride, cyclooxygenase inhibitor, prostaglandin receptor antagonist, prostaglandin receptor agonist, Thymic stromal lymphopoietin (TSLP) production inhibitor, adenylate cyclase inhibitor, omega-3 fatty acid, peroxisome proliferator-activated receptor (PPAR) agonist, dopamine receptor antagonist, dopamine receptor agonist, histamine receptor agonist, histamine receptor antagonist, serotonin receptor agonist, serotonin receptor antagonist, vasopressin receptor antagonist, vasopressin receptor agonist, muscarine receptor antagonist, muscarine receptor agonist, adrenergic receptor antagonist, adrenergic receptor agonist, angiotensin receptor agonist, GABA receptor agonist, thrombin receptor antagonist, thrombin receptor agonist, opioid receptor agonist, Adenosine diphosphate (ADP) receptor agonist, leukotriene receptor antagonist, leukotriene receptor agonist, melatonin receptor agonist, somatostatin receptor agonist, cannabinoid receptor agonist, sphingosine-1 phosphate receptor agonist, metabotropic glutamate receptor agonist, phospholipase A2 inhibitor, TGF-ß production inhibitor, and Th2 cytokine inhibitor all for the treatment and prevention of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; lotions for pharmaceutical purposes for skin, mucosal membrane, and body; lotions for veterinary purposes for skin, mucosal membrane, and body; medicated lozenges for pharmaceutical purposes; medical plasters; medicinal drinks; medicines for dental purposes; medicines for human purposes, namely, pharmaceutical preparations for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; medicines for veterinary purposes, namely, pharmaceutical preparations for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; mouthwashes for medical purposes; ointments for pharmaceutical purposes, namely, vaccines; oral vaccine preparations; medicated pastilles for pharmaceutical purposes; petroleum jelly for medical purposes; pharmaceutical preparations for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for skin care; pomades for medical purposes; poultices; Pharmaceutical preparations for therapy of immunity for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; preparations of microorganisms for medical and veterinary purposes the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; siccatives for medical purposes; sticking plasters for medical purposes; syrups for pharmaceutical purposes for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; therapeutic drug for therapy of immunity, namely, vaccines; tissues impregnated with pharmaceutical lotions for the prevention and treatment of infectious disease, cancer, allergy, autoimmune disease and other disease related with immunity; vaccine adjuvants; vaccine preparations; vaccines; vaccines against influenza; vaccines against pneumococcal infections; vaccines for cattle; vaccines for dogs; vaccines for horses; vaccines for human or animal; vaccines for human use; vaccines or preparations used in the treatment of cancer; veterinary vaccinesSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 1, 2025DETHDEATH OF INTERNATIONAL REGISTRATION—
Jul 31, 2023INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Jul 11, 2023INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Jul 11, 2023INPCINVALIDATION PROCESSED—
Jun 7, 2023INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Oct 7, 2022C71TCANCELLED SECTION 71—
Jul 15, 2016FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jun 22, 2016FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jun 22, 2016FIMPFINAL DISPOSITION PROCESSED—
Jun 22, 2016FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 22, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 5, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 4, 2016GPNXNOTIFICATION PROCESSED BY IB—
Dec 16, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Dec 16, 2015OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Dec 16, 2015NPUBNOTICE OF PUBLICATION—
Nov 30, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 20, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 20, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 20, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 13, 2015ALIEASSIGNED TO LIE—
Oct 26, 2015ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Sep 21, 2015CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 18, 2015CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 28, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 28, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 28, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 11, 2015RFNTREFUSAL PROCESSED BY IB—
Jun 30, 2015MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 25, 2015RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 25, 2015RFRRREFUSAL PROCESSED BY MPU—
Jun 25, 2015RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 24, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 24, 2015DOCKASSIGNED TO EXAMINER—
Jun 24, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 18, 2015REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance